PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
CONCLUSION: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.PMID:37833089 | PMC:PMC10575658 | DOI:10.46747/cfp.6910675 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Michael R Kolber Scott Klarenbach Michel Cauchon Mike Cotterill Loren Regier Raelene D Marceau Norah Duggan Rebecca Whitley Alex S Halme Tanis Poshtar G Michael Allan Christina S Korownyk Joey Ton Liesbeth Froentjes Samantha S Moe Danielle Perry Betsy S T Source Type: research
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews
CONCLUSION: Statins have the most consistent evidence for the prevention of cardiovascular complications with a relative risk reduction of about 25% for MACE and 10% to 15% for mortality. The addition of ezetimibe, a PCSK9 inhibitor, or eicosapentaenoic acid ethyl ester to a statin provides additional MACE risk reduction but has no effect on all-cause mortality.PMID:37833094 | PMC:PMC10575662 | DOI:10.46747/cfp.6910701 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Nicolas Dugr é Adrienne J Lindblad Danielle Perry G Michael Allan Émélie Braschi Jamie Falk Liesbeth Froentjes Scott R Garrison Jessica E M Kirkwood Christina S Korownyk James P McCormack Samantha S Moe Allison Paige Jen Potter Betsy S Thomas Joey Ton Source Type: research
PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
CONCLUSION: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.PMID:37833089 | PMC:PMC10575658 | DOI:10.46747/cfp.6910675 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Michael R Kolber Scott Klarenbach Michel Cauchon Mike Cotterill Loren Regier Raelene D Marceau Norah Duggan Rebecca Whitley Alex S Halme Tanis Poshtar G Michael Allan Christina S Korownyk Joey Ton Liesbeth Froentjes Samantha S Moe Danielle Perry Betsy S T Source Type: research
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews
CONCLUSION: Statins have the most consistent evidence for the prevention of cardiovascular complications with a relative risk reduction of about 25% for MACE and 10% to 15% for mortality. The addition of ezetimibe, a PCSK9 inhibitor, or eicosapentaenoic acid ethyl ester to a statin provides additional MACE risk reduction but has no effect on all-cause mortality.PMID:37833094 | PMC:PMC10575662 | DOI:10.46747/cfp.6910701 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Nicolas Dugr é Adrienne J Lindblad Danielle Perry G Michael Allan Émélie Braschi Jamie Falk Liesbeth Froentjes Scott R Garrison Jessica E M Kirkwood Christina S Korownyk James P McCormack Samantha S Moe Allison Paige Jen Potter Betsy S Thomas Joey Ton Source Type: research
PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
CONCLUSION: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.PMID:37833089 | PMC:PMC10575658 | DOI:10.46747/cfp.6910675 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Michael R Kolber Scott Klarenbach Michel Cauchon Mike Cotterill Loren Regier Raelene D Marceau Norah Duggan Rebecca Whitley Alex S Halme Tanis Poshtar G Michael Allan Christina S Korownyk Joey Ton Liesbeth Froentjes Samantha S Moe Danielle Perry Betsy S T Source Type: research
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews
CONCLUSION: Statins have the most consistent evidence for the prevention of cardiovascular complications with a relative risk reduction of about 25% for MACE and 10% to 15% for mortality. The addition of ezetimibe, a PCSK9 inhibitor, or eicosapentaenoic acid ethyl ester to a statin provides additional MACE risk reduction but has no effect on all-cause mortality.PMID:37833094 | PMC:PMC10575662 | DOI:10.46747/cfp.6910701 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Nicolas Dugr é Adrienne J Lindblad Danielle Perry G Michael Allan Émélie Braschi Jamie Falk Liesbeth Froentjes Scott R Garrison Jessica E M Kirkwood Christina S Korownyk James P McCormack Samantha S Moe Allison Paige Jen Potter Betsy S Thomas Joey Ton Source Type: research
PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
CONCLUSION: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.PMID:37833089 | PMC:PMC10575658 | DOI:10.46747/cfp.6910675 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Michael R Kolber Scott Klarenbach Michel Cauchon Mike Cotterill Loren Regier Raelene D Marceau Norah Duggan Rebecca Whitley Alex S Halme Tanis Poshtar G Michael Allan Christina S Korownyk Joey Ton Liesbeth Froentjes Samantha S Moe Danielle Perry Betsy S T Source Type: research
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews
CONCLUSION: Statins have the most consistent evidence for the prevention of cardiovascular complications with a relative risk reduction of about 25% for MACE and 10% to 15% for mortality. The addition of ezetimibe, a PCSK9 inhibitor, or eicosapentaenoic acid ethyl ester to a statin provides additional MACE risk reduction but has no effect on all-cause mortality.PMID:37833094 | PMC:PMC10575662 | DOI:10.46747/cfp.6910701 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Nicolas Dugr é Adrienne J Lindblad Danielle Perry G Michael Allan Émélie Braschi Jamie Falk Liesbeth Froentjes Scott R Garrison Jessica E M Kirkwood Christina S Korownyk James P McCormack Samantha S Moe Allison Paige Jen Potter Betsy S Thomas Joey Ton Source Type: research
PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
CONCLUSION: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.PMID:37833089 | PMC:PMC10575658 | DOI:10.46747/cfp.6910675 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Michael R Kolber Scott Klarenbach Michel Cauchon Mike Cotterill Loren Regier Raelene D Marceau Norah Duggan Rebecca Whitley Alex S Halme Tanis Poshtar G Michael Allan Christina S Korownyk Joey Ton Liesbeth Froentjes Samantha S Moe Danielle Perry Betsy S T Source Type: research
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews
CONCLUSION: Statins have the most consistent evidence for the prevention of cardiovascular complications with a relative risk reduction of about 25% for MACE and 10% to 15% for mortality. The addition of ezetimibe, a PCSK9 inhibitor, or eicosapentaenoic acid ethyl ester to a statin provides additional MACE risk reduction but has no effect on all-cause mortality.PMID:37833094 | PMC:PMC10575662 | DOI:10.46747/cfp.6910701 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Nicolas Dugr é Adrienne J Lindblad Danielle Perry G Michael Allan Émélie Braschi Jamie Falk Liesbeth Froentjes Scott R Garrison Jessica E M Kirkwood Christina S Korownyk James P McCormack Samantha S Moe Allison Paige Jen Potter Betsy S Thomas Joey Ton Source Type: research
PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
CONCLUSION: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.PMID:37833089 | PMC:PMC10575658 | DOI:10.46747/cfp.6910675 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Michael R Kolber Scott Klarenbach Michel Cauchon Mike Cotterill Loren Regier Raelene D Marceau Norah Duggan Rebecca Whitley Alex S Halme Tanis Poshtar G Michael Allan Christina S Korownyk Joey Ton Liesbeth Froentjes Samantha S Moe Danielle Perry Betsy S T Source Type: research
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews
CONCLUSION: Statins have the most consistent evidence for the prevention of cardiovascular complications with a relative risk reduction of about 25% for MACE and 10% to 15% for mortality. The addition of ezetimibe, a PCSK9 inhibitor, or eicosapentaenoic acid ethyl ester to a statin provides additional MACE risk reduction but has no effect on all-cause mortality.PMID:37833094 | PMC:PMC10575662 | DOI:10.46747/cfp.6910701 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Nicolas Dugr é Adrienne J Lindblad Danielle Perry G Michael Allan Émélie Braschi Jamie Falk Liesbeth Froentjes Scott R Garrison Jessica E M Kirkwood Christina S Korownyk James P McCormack Samantha S Moe Allison Paige Jen Potter Betsy S Thomas Joey Ton Source Type: research
PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
CONCLUSION: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.PMID:37833089 | PMC:PMC10575658 | DOI:10.46747/cfp.6910675 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Michael R Kolber Scott Klarenbach Michel Cauchon Mike Cotterill Loren Regier Raelene D Marceau Norah Duggan Rebecca Whitley Alex S Halme Tanis Poshtar G Michael Allan Christina S Korownyk Joey Ton Liesbeth Froentjes Samantha S Moe Danielle Perry Betsy S T Source Type: research
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews
CONCLUSION: Statins have the most consistent evidence for the prevention of cardiovascular complications with a relative risk reduction of about 25% for MACE and 10% to 15% for mortality. The addition of ezetimibe, a PCSK9 inhibitor, or eicosapentaenoic acid ethyl ester to a statin provides additional MACE risk reduction but has no effect on all-cause mortality.PMID:37833094 | PMC:PMC10575662 | DOI:10.46747/cfp.6910701 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Nicolas Dugr é Adrienne J Lindblad Danielle Perry G Michael Allan Émélie Braschi Jamie Falk Liesbeth Froentjes Scott R Garrison Jessica E M Kirkwood Christina S Korownyk James P McCormack Samantha S Moe Allison Paige Jen Potter Betsy S Thomas Joey Ton Source Type: research
PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
CONCLUSION: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.PMID:37833089 | PMC:PMC10575658 | DOI:10.46747/cfp.6910675 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Michael R Kolber Scott Klarenbach Michel Cauchon Mike Cotterill Loren Regier Raelene D Marceau Norah Duggan Rebecca Whitley Alex S Halme Tanis Poshtar G Michael Allan Christina S Korownyk Joey Ton Liesbeth Froentjes Samantha S Moe Danielle Perry Betsy S T Source Type: research
